Small extracellular vesicle-derived circular RNA hsa_circ_0007386 as a biomarker for the diagnosis of Pleural Mesothelioma

Small extracellular vesicle-derived circular RNA hsa_circ_0007386 as a biomarker for the diagnosis of Pleural Mesothelioma | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Small extracellular vesicle-derived circular RNA hsa_circ_0007386 as a biomarker for the diagnosis of Pleural Mesothelioma Sareh Zhand, Jiayan Liao, Alessandro Castorina, Man Lee Yuen, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4107936/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 14 Jun, 2024 Read the published version in Cells → Version 1 posted You are reading this latest preprint version Abstract Pleural mesothelioma (PM) is a highly aggressive tumor that is caused by asbestos exposure and lacks effective therapeutic regimens. Current procedures for PM diagnosis are invasive and can take a long time to reach a definitive result. Small extracellular vesicles (sEVs) have been identified as important communicators between tumour cells and their microenvironment via their cargo including circular RNAs (circRNAs). CircRNAs are thermodynamically stable, highly conserved and it has been found to be dysregulated in cancer. This study aimed to identify potential biomarker for PM diagnosis by investigating the expression of specific circRNA gene pattern (hsa_circ_0007386) in cells and sEVs using digital polymerase chain reaction (dPCR). For this reason, 5 PM, 14 non-PM, and one normal mesothelial cell line were cultured. The sEV were isolated from the cells using the gold standard ultracentrifuge method. The RNA was extracted from both cells and sEVs, cDNA was synthesised, and dPCR was run. Results showed that hsa_circ_0007386 was significantly overexpressed in PM cell lines and sEVs compared to non-PM and normal mesothelial cell lines (p<0.0001). The upregulation of hsa_circ_0007386 in PM highlights its potential as a diagnostic biomarker. This study underscores the importance and potential of circRNAs and sEVs as cancer diagnostic tools. Biological sciences/Cancer Biological sciences/Molecular biology Health sciences/Biomarkers Pleural Mesothelioma small extracellular vesicle circular RNA digital PCR Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Introduction Pleural mesothelioma (PM) is an aggressive cancer of the lung lining that occurs as a result of previous asbestos exposure either occupationally or environmentally (1). The lack of specific biomarkers and different pathologic subtypes increase the difficulty of diagnosis and treatment. PM patients are usually diagnosed at an advanced stage and are usually short lived with median survival ranging from 4 to 18 months (2, 3) and five year survival rate currently stands at less than 5% (4). Additionally, therapeutic options for PM patients who are not eligible for surgery are very limited (5). There are three main histological subtypes of PM: epithelioid, biphasic, and sarcomatoid (6). While epithelioid PM shows a morphology similar to normal pleura, biphasic and sarcomatoid subtypes are associated with a worse prognosis than the epithelioid subtype (7). The PM exhibits a highly secretory cell type, releasing factors that can exert autocrine or paracrine effects on nearby tumor and stromal cells. These released factors likely contribute to the modulation of the extracellular environment and could potentially serve as a source for identifying cancer biomarkers(8). Current procedures for PM diagnosis are invasive and can take a long time to reach a definitive result (9-11). As the incidence of PM continues to rise, there is a pressing need for novel biomarkers for early detection. These tools and biomarkers are crucial for effective clinical management of PM, facilitating early diagnosis, monitoring prognosis, and predicting treatment outcomes (12). In recent times, extracellular vesicles (EVs) have garnered attention as significant messengers facilitating communication between tumor cells and their surrounding microenvironment. These extracellular vesicles have emerged as key mediators in cancer biology, orchestrating cellular communication crucial to tumorigenesis and harbouring distinctive cancer biomarker profiles (13). EVs stand as promising candidates for both diagnosis and therapy owing to their detectability in non-invasive blood samples and other body fluids. This characteristic suggests significant potential for their application in diagnostic and therapeutic endeavours. The EVs released from mesothelioma cells provide crucial insights into the molecules and signalling pathways pivotal in the initiation and advancement of the tumour (14). As delineated by the International Society of Extracellular Vesicles (ISEV), the designation "small extracellular vesicles" is the recommended nomenclature for the diverse array of vesicles derived from cell culture supernatants or physiological fluids. (15, 16). EVs, particularly small extracellular vesicles (sEVs), represent a heterogeneous population of lipid-bilayer-delimited particles released from cells that are classified based on size (17-19). This nano sized particles (30–150 nm) originating from the endosomal pathway, play essential roles in both physiological and pathological phenomena, (22, 23), encompassing crucial functions in immune response (20), signal transduction (21), as well as tumor initiation, progression, invasion, and metastasis (22, 23). These vesicles exhibit enrichment in a repertoire of shared structural and functional proteins, including tetraspanins (CD9, CD81, CD82, and CD63) (24), Rab GTPase, and HSP90 (heat shock protein 90), among others (25). Furthermore, sEVs transport a diverse cargo comprising of proteins, nucleic acids (mRNA, regulatory RNA, and DNA components), lipids, metabolites, and organelles from donor cells. Recent findings suggest that these reservoirs of biomarkers hold promise for advancing early cancer detection, prognostication, and monitoring tumor progression. (26-28). In recent investigations, it has been established that Osteopontin, Galectin-1, Mesothelin, and VEGF exhibit elevated concentrations in sEVs derived from PM patients' effusions in comparison to those from the benign group (14). Furthermore, another study revealed increased expression levels of Galectin-1, Mesothelin, Osteopontin, and VEGF in PM patients relative to benign patients (15) (15). Some EV biomarkers were found to be abundant in the serum of mice exposed to asbestos, as well as elevated levels of exosomal ceruloplasmin, haptoglobin, and fibulin-1 (16). The sEVs represent a largely untapped resource of diagnostic, prognostic, and predictive biomarkers with significant potential for clinical applications. (18, 29, 30). Circular RNA (circRNA) presents a distinct form of non-coding RNA characterized by its closed single-stranded structure lacking 5’ caps or 3’ poly(A) tails, setting it apart from linear messenger RNA (mRNA)(31). They are originating from pre-mRNAs through a process termed back splicing (32). CircRNAs exhibit remarkable stability in the bloodstream and possess a longer half-life compared to linear RNAs. Additionally, they exhibit resistance to exonuclease-mediated degradation, rendering them highly attractive candidates for blood-based diagnostic applications (33). Recent investigations have unveiled a correlation between circRNA overexpression and tumorigenesis across various cancers, encompassing lung malignancies (including PM), liver, breast, prostate, bladder, colorectal, ovarian, central nervous system, stomach, as well as diverse haematological malignancies (34). Published findings indicate a significant enrichment of circRNAs within sEVs, with levels exceedingly at least two-fold those observed in parental cells (35). Recent studies highlighted the abundance and stability of circular RNAs within sEVs, suggesting their persistent functionality after up taking by neighbouring cells (35). Exo-circRNAs produced by tumors are released into bodily fluids, where they exert effects on various aspects including diagnosis, suppression of metastasis, and induction of tumor cell apoptosis (44). It has been suggested that cells may transfer circRNAs by excreting them in sEVs, acting as messengers in cell-to-cell communication, and studies also propose that the clearance of intracellular circRNAs may be associated with sEVs (36). There is currently limited knowledge on circRNA expression in PM (37) and CircRNA expression in sEV derived from PM has not been explored yet. This study aims to use the digital PCR (dPCR) for an accurate detection of the most frequently upregulated circRNA in PM (hsa_circ_0007386) in sEVs derived from PM, non-PM and normal mesothelial cell lines and compare the expression of this specific circRNA with non-PM and normal mesothelial cell line to determine its suitability as potential biomarker candidate for the early diagnosis of PM (Fig. 1). Result and Discussion The sEVs exist in various body fluids, which is convenient for non-invasive detection (38). CircRNAs are stable, conservative, and specific expression of cells and tissues, which suggests that they have the potential to be used as molecular diagnostic and prognostic markers (39). sEV derived circRNAs combine the advantages of using sEVs with the specificity of circRNAs, enhancing their potential application as early non-invasive biomarkers. sEVs derived from pathological cells can carry their disease-specific circRNA into the peripheral blood. Therefore, the detection of sEV-derived circRNAs in serum may be feasible in the diagnosis of tumor disease. CircRNAs have also been considered as EV biomarkers to monitor the progression and chemoresistance of some type of cancers. In addition, it has been discovered that circRNAs are stably expressed in sEVs and these circRNAs are suggested to be a promising candidate for biomarkers in cancer (40). CircRNA expression profile in mesothelioma According to results of our previous study (37), 290 circRNAs derived from host genes PHKB, SLC45A4, ARHGEF28, FBXW4, TAF15, PLEKHM1, RALGPS1, STIL, L3MBTL4, ANKRD27, NHS, ILKAP, and PTK2 in PM cell lines were upregulated using high throughput human lncRNA microarrays through fold change (FC) (37). For this paper, we selected hsa_circ_0007386 (the one most highly expressed in four mesothelioma cells) as a representative circRNA for the PHKB gene (37) and investigated for changes in its expression levels to determine whether it could be employed as a potential biomarker for PM diagnosis. sEV characterization For sEV characterization, particle size and concentration were evaluated by NTA, the morphology was evaluated with Cryo-EM and the expression of the sEV common protein markers (CD63, CD81, and CD9) was assessed using Western blotting (Fig.2). The tetraspanins (CD63, CD81, and CD9) were detected in the sEVs derived from studied cell line using Western Blotting (Fig. 2 A & Fig. 1A-E Supplementary information). The size distribution of sEVs, measured by NTA and the concentration of sEVs enriched from cells is shown in Fig. 2B. As shown in Fig. 2C, most of the particles had a mean size of 100-200 nm. For more and precise characterisation of the sEVs, the Cryo-EM imaging was performed. Under cryo-EM, the specimens were imaged under extremely low temperature (below − 175 °C) so that sEVs retained its original spherical shape. The results of cryo-EM for sEVs confirmed their expected size and morphology (Fig. 2D). The hsa_circ_0007386 RNA binding sites. Numerous databases are available for RNA binding sites to circRNA targets. In this study, we have used the Circular RNA interactome database (https://circinteractome.nia.nih.gov/) to find out the RNA-binding sites matching. The results are listed in Fig. 3. The hsa_circ_0007386 highly expressed in PM cell lines and sEVs. For the digital PCR analysis, the negative control for the hsa_circ_0007386 was used to adjust the threshold for achieving the correct signal from the positive samples and the signal detected from the top right corner of the quadruplet, regarded as a positive control. In all samples, the background signal was used as the threshold above which signals were considered positive. Results of digital PCR revealed that among the studied cell lines, the hsa_circ_0007386 was overexpressed in NCI H-28 cells, with 1218.3 copies per µL input sample, followed by the H2052, H226, H2452, and MSTO-211H, with 696.7, 555.6, 412.5, and 187 copies per µL, respectively. The normal mesothelial cell line (MeT5A) showed 448 copies per µL. By normalizing the copy numbers using the ratio of hsa_circ_0007386 to hsa_circ_0000284, ratios were 0.183, 0.168, 0.098, 0.0943, and 0.0908 respectively (Fig. 4A). Based on findings by Zhong at al.,(41) hsa_circ_0000284 was selected as the internal control due to its demonstrated superior stability. This characteristic renders it an optimal candidate not only for circRNAs but also for broader RNA applications, serving as a reliable reference gene (41). The results also indicate that the copy number ratio of hsa_circ_0007386 to the circ RNA reference was significantly lower in non-PM cell lines including melanoma (Colo794; 0.0340, Colo679;0.0042, A375; 0.00755), gastric (Kato III; 0.0467, MKN45;0.0066), lung (H460; 0.031, H3122; 0.0167), colon (HCT 115;0.0216, HCT 116;0.0323), breast (MCF-7; 0.0235), liver (HepG2;0.068), and prostate (LnCAP; 0.00433) cancer cell lines (p<0.0001). the hsa_circ_0007386 was overexpressed in H226 derived sEVs, with 36.23 copy per µL, followed by MSTO-211H, H2452, H2052, and NCI-H28, with 23, 11.71, 9.54, and 6.77 copies per µL of mixture, respectively. By normalizing the copy numbers found in sEVs using the hsa_circ_0007386 to hsa_circ_0000284 ratio, results differed from those attained using cells RNA extracts, and so did the ranking across cell lines as follows; H2452, NCI-H28, MSTO-211H, H2052, and H226 with the following ratios 0.187, 0.171, 0.121, 0.1045, and 0.087, respectively (Fig. 4B). Interestingly, the copy number ratio of this circRNA biomarker to the circ RNA reference was significantly lower in non-PM cell lines including melanoma (Colo 794; 0.0580, Colo679;0.0053, A375; 0.0084), gastric (Kato III; 0.055, MKN45;0.0054), lung (H460; 0.036, H3122; 0.032,), colon (HCT 116;0.0452, HCT 115; 0.018), breast (MCF-7; 0.0233), and prostate (LnCAP; 0.0066) cancer cell lines (p<0.0001). Indicating that the sorting of specific circRNA species to sEVs compared to the cells may be actively regulated. Results of our study revealed the specificity of the has_circ_0007386 derived from both cells and sEVs as a specific biomarker for early diagnosis of PM, as we have observed significant expression of this biomarker in the PM cell derived sEVs (Fig. 5A) and PM cell lines (Fig. 5B) compared to the normal mesothelial cell line (Met5A) and the microglial cell line (BV-2) (p<0.0001). The results of our study on PM and non-PM cells derived RNAs confirm the 90% sensitivity and 93.3% specificity of the hsa_circ_0007386 as a biomarker in PM diagnosis. However, this number was 81.81% and 87.5% in the sEV respectively. The specificity was calculated by dividing the number of true negative samples which are here non-PM cell lines to the sum of true negative and false positive which are here sum pf non-PM cell lines and the cell lines that shows higher ratio of has_circ_0007386 to reference circRNA compared to the PM cell lines (42). Similarly for the sensitivity calculation, the number of true positive samples which are here PM cell lines to the sum of true positive and false negative which are here sum of PM cell lines and the cell lines that shows higher ratio of has_circ_0007386 to reference circRNA compared to the PM cell lines (42). While our results demonstrate consistencies in the copy numbers or copy number ratios of hsa_circ_0007386 and hsa_circ_0000284 between PM, and non-PM derived sEV samples and their corresponding cellular counterparts, the findings also reveal a higher copy number ratio of hsa_circ_0007386 to the reference hsa_circ_0000284 in sEV-derived samples compared to the cells. The heightened presence of hsa_circ_0007386 within PM-derived sEVs, as compared to its cellular counterpart, underscores the propensity of circRNAs for encapsulation within sEVs. By scrutinizing the contents of sEVs, we can attain more precise and sensitive findings than those derived from the analyses of cellular extracts alone. Notably, our investigation revealed the maximal copy number of sEV-derived hsa_circ_0007386 within MSTO-211H, representative of the biphasic variant of PM. Early identification of this PM subtype holds substantial promise for advancing our understanding of disease progression. Consequently, the potential clinical value of sEV-derived hsa_circ_0007386 in less-invasive liquid biopsy approaches deserves consideration, with the outlook of replacing traditional tissue biopsies in the future. Our findings underscore the diagnostic specificity of hsa_circ_0007386 as a viable biomarker for early PM detection, with significantly elevated expression observed in PM cell lines compared to non-PM, normal mesothelial, and other cancer cell lines (p-value < 0.0001). This highlights the promising diagnostic potential of hsa_circ_0007386 across both sEV and cellular contexts. To ensure precision and reliability, further validation utilizing patient samples is imperative for consolidating these outcomes. In different stages of different development diseases, disease-related circRNA can be sorted into sEVs to be enriched and transported to target cells or target organs for release. Many studies have shown that differential expression of sEV-derived circRNAs in the body fluid was associated with the pathological characteristics of tumor vascular invasion, lymph node metastasis, poor survival and TNM stage (43-45). Studies have shown that circRNAs can be packaged and function in sEVs (46). However, the mechanism behind the selective packaging of specific circRNAs into sEVs is not yet clear and requires further investigation. In a study by Zhang et al (47), it was showed that circRNA polo-like kinase 1 (circPLK1) was upregulated in Malignant Pleural Mesothelioma (MPM) tumor tissues and cell lines. CircPLK1 knockdown suppressed the proliferation, migration, invasion and stemness of MPM cells in MPM progression. The studies mentioned have indicated the diagnostic efficacy of different circ-RNAs as a cancer marker. In the PM cell derived sEVs, a notable observation arose when comparing the copy number ratio of hsa_circ_0007386 to the circRNA reference across various PM cell derived sEVs, particularly in the context of one lung cancer cell line (H1975), and one liver cancer (HepG2). Despite an apparently higher ratio in H1975 (0.1630), and HepG2 (0.086) compared to other PM cell lines (H20525, MSTO-211H, and H226) a deeper analysis utilizing raw data and absolute copy number calculations revealed that the observed copy number of this putative circRNA biomarker in the above-mentioned cell lines did exhibit statistical significance (p<0.0001) (Fig. 6A). The decision to employ exact copy number calculations was driven by the criterion of fewer than 100 copies per 40 µL of digital PCR sample, aiming to enhance result accuracy. Similarly, in the PM cell lines, comparable to our observations in the cell derived sEVs, a notable observation arose when comparing the copy number ratio of hsa_circ_0007386 to the circRNA reference across various PM cell lines, particularly in the context of one lung cancer cell line (H1975). Despite an apparently higher ratio in H1975 (0.12) compared to other PM cell lines (MSTO-211H, H226, and H2452), a deeper analysis utilizing raw data and absolute copy number calculations revealed that the observed copy number of this putative circRNA biomarker in the H1975 cell line did exhibit statistical significance (p<0.0001) (Fig. 6B). The decision to employ exact copy number calculations was driven by the criterion of fewer than 100 copies per 40 µL of digital PCR sample, aiming to enhance result accuracy (48). Results of a systematic review and meta-analysis revealed that circRNAs have the potential to be biomarkers for diagnosis and prognosis of cancers (49). It has been described by Stella et al. that two circRNAs that localised in serum derived sEVs including circSMARCA5 (hsa_circ_0001445) and circHIPK3 (hsa_circ_0000284) could be potential biomarkers for glioblastoma and could distinguish glioblastoma patients from healthy controls with high accuracy (50). In contrast, another study has reported that the continued high expression of sEV derived circRNA-100338 in the serum of HCC HCC (Hepatocellular Carcinoma) patients undergoing therapeutic hepatectomy may be related to lung metastasis and poor survival (51). There are some advantages in analyzing sEV-encapsulated non-coding RNAs compared to whole plasma/serum. Firstly, as extracellular vesicles can be secreted by a variety of cells, the contents of sEVs can be used as biomarkers for diagnosis or prognosis in various diseases (52). Secondly, it is easier to sort circRNA into sEVs than linear RNAs (35). In addition, sEVs derived from cancers contain highly specific RNA, and they can also prevent the nucleic acid molecules from degradation by RNase in the blood (53). However, there are still many issues to be resolved before sEVs-derived circRNAs can be employed as reliable biomarkers, such as preservation of specimens, cell source of sEVs, sEVs isolation methods, etc. Future investigations focusing on sEV circRNAs in various biological contexts, such as the hematopoietic system, immune response, nervous disorders, cancer development, and other diseases, will provide further insights into the enigmatic nature of sEV circRNAs. Consequently, elucidating the mechanisms of cancer pathogenesis and identifying potential novel diagnostic biomarkers or therapeutic targets are expected to be prominent areas of research in the future. Materials and methods Reagents The list of following antibodies including purified anti-human CD63 (Clone H5C6), purified anti-human CD9 (Clone HI9a), and purified anti-human CD81 (Clone 5A6) antibodies, along with the secondary antibody HRP-goat anti-mouse IgG (405306), were purchased from BioLegend (USA). BenchMark™ Pre-stained Protein Ladder (10748010) and Novex™ Sharp Pre-stained Protein Standard (LC5800) were obtained from ThermoFisher (USA). RIPA Lysis and Extraction Buffer (89900), Pierce BCA protein assay kit (23227), 4X Bolt™ LDS Sample Buffer (B0007), polyvinylidene difluoride (PVDF) transfer membranes (88585), Bolt™ 4-12% Bis-Tris Plus Gels (NW04120BOX), Glycogen (R0561), and SuperSignal™ West Dura Extended Duration Substrate (37071) were purchased from Life Technologies (Australia). TRIzol LS (10296010, Invitrogen, USA), phosphate buffered saline (PBS), Bovine serum albumins (A3059-10G), Chloroform (288306-1L), Isopropanol (I9516-500ML), Ethyl alcohol (E7023), and 1,4-dithiothreitol (DTT) (10197777001) were purchased from Sigma Aldrich (USA). High-Capacity cDNA Reverse Transcription Kit (4368813) was purchased from Applied Biosystems, USA. The QIAcuity Probe PCR Kit (250102), and QIAcuity Nanoplate 26k 24-well (250001) was purchased from Qiagen, USA. Cell culture 1 and repeatedly tested negative for mycoplasma in house at UTS. All cells were maintained in RPMI 1640 (Gibco, UK) supplemented with 10% (v/v) fetal calf serum (FCS, Gibco, UK), 100 U/mL penicillin and 100 mg/mL streptomycin (Gibco, UK) in a T25 tissue culture flask (ThermoFisher, USA) The cultures were maintained at 37°C in a humidified incubator with 5% CO 2 and for BV-2 cell line the RPMI 1460 was replaced with DMEM: F12. Total RNA Isolation The comprehensive procedure for RNA isolation has been previously documented in our publication (54). In brief, approximately 1×10 6 cell pellets were utilized for the isolation of total RNA using the TRIzol extraction method. Following the manufacturer’s protocol, 750µL of TRIzol Reagent was combined with 250µL of cell pellets, and the mixture was homogenized through repeated pipetting. After a 5-minute incubation to ensure complete dissociation of the nucleoprotein complex, 200µL of chloroform was added for lysis and incubated at room temperature for 2–3 minutes. Subsequently, the samples underwent centrifugation at 12,000 × g for 15 minutes at 4°C, resulting in phase separation. The upper aqueous phase, containing the RNA, was transferred to a new tube, and 500µL of isopropanol along with 1 µL of Glycogen was added, followed by a 10-minute incubation. After centrifugation at 12,000 × g for 10 minutes at 4°C, the RNA precipitate formed a white gel-like pellet at the bottom of the tube, and the supernatant was discarded. The pellet was then resuspended in 1 mL of 75% ethanol and centrifuged at 7500 × g for 5 minutes at 4°C. Following removal of the supernatant, the RNA pellet was air dried for 5–10 minutes, then resuspended in 20 µL of RNase-free water and incubated in a heat block at 60°C for 15 minutes. Finally, the RNA samples were stored at –70°C for subsequent use. Quantification of the extracted RNA samples was performed using the NanoDrop™ One Microvolume UV-Vis Spectrophotometer (Thermo Scientific). cDNA Synthesis 1µg of total RNA was subjected to first-strand complementary DNA (cDNA) synthesis using a high-capacity cDNA reverse transcription kit (4368813, Applied Biosystems, USA) consisting of random hexamers and additional 50µM of Oligo dT primer, in the following conditions: primer annealing at 25°C for 10 minutes, cDNA synthesis at 37°C for 2 hours, denaturing at 85°C for 5 minutes and for 1 cycle using a CFX96 PCR system (Bio-Rad, Hercules, CA, USA). The cDNA was stored at -20ºC for further experiments. CircRNA detection via digital PCR The digital PCR was done using the QIAcuity Probe PCR kit (250102, Qiagen, USA) according to manufacturer’s protocol. 1x concentration of probe PCR master mix, 0.8 μM forward primer (hsa_circ_0007386), 0.8 μM reverse primer (hsa_circ_0007386), and 0.4 μM probe (hsa_circ_0007386), 12µL of each synthesized cDNA sample in a total volume of 40μL was added to the Nanoplate 26k (Qiagen, USA). Similarly, Amplification conditions consisted of 1 cycle of 95˚C for 2 min following 40 cycles of 95˚C for 15 sec, and 60˚C for 30 seconds with plate read. The cycling and detection were performed on QIAcuity digital PCR system. All experiments were normalized with respective hsa_circ_0000284 as a reference gene expression. Hsa_circ_0000284 is utilized as a reference gene for this study in order to normalize the detected circRNA copy number variation for each tested sample. The prime/ probes used in the study are listed in our previous work (37). Preparation of conditioned medium (CM) The comprehensive procedure for preparing CM has been previously documented in our earlier publication (55). Briefly, for CM preparation from the above-mentioned cell lines, the cells were initially cultured in T175 tissue culture flasks (ThermoFisher, USA). Upon reaching approximately 70% confluency, equivalent to approximately 3×10 8 cells, the supernatant was carefully removed, and the cells underwent two washes with phosphate-buffered saline (PBS). Subsequently, the cells were transferred to sEV-free medium (RPMI 1640/DMEM: F12 without FCS) and cultured for 48 hours at 37°C in a humidified incubator set at 5% CO 2 and 2% O 2 (hypoxic conditions). Following incubation, the culture medium was collected for further experimentation. Small EV isolation from CM using ultracentrifugation. The comprehensive procedure for sEV isolation has been previously documented in our publication (54). The media containing released EVs was initially subjected to centrifugation steps to eliminate cellular debris. This process involved centrifugation at 300 ×g (19776 rotor, Sigma, USA) for 10 minutes to remove dead cells and debris, followed by a subsequent centrifugation at 2,000 ×g (19776 rotor, Sigma, USA) for 20 minutes to further eliminate debris. The resulting cell-free supernatant was then transferred to a new tube and centrifuged at 10,000 ×g (19776 rotor, Sigma, USA) for 30 minutes to pellet microvesicles. The supernatant containing EVs was subsequently filtered through a sterile 0.22 µm syringe filter (Merck Millipore, USA) and subjected to ultracentrifugation at 100,000 ×g for 120 minutes (F37L Ti rotor, Beckman Coulter, USA) to pellet small EVs (sEVs). After removal of the supernatant, pellets containing EVs and contaminating proteins were re-suspended in a separate ultracentrifuge tube in phosphate-buffered saline (PBS) and centrifuged again at 100,000 ×g for 120 minutes. The supernatant was discarded, and the pellet was resuspended in 500 µL of PBS, previously filtered through a 0.22 µm syringe filter (WHA9913-2502, Sigma Aldrich, USA). The isolated sEVs were stored at -80°C until further use. All centrifugation steps were conducted at 4ºC. Nanoparticle tracking analysis. For nanoparticle tracking analysis (NTA), a ZetaView® PMX-420 QUATT system (Particle Metrix, Germany) equipped with a 532nm green laser was employed to determine the concentration and size distribution of small extracellular vesicles (sEVs). Isolated sEV samples (100µL) were diluted to 500µL using freshly filtered PBS (0.22µm filter) and injected into the detection chamber via syringe. The camera settings, including a slider shutter at 650 and slider gain at 50, were manually adjusted and maintained consistently across all samples. Videos lasting 30 seconds were recorded, with 5 captures per sample. The detection threshold was set at 6, while blur and max jump distance were automatically configured. The temperature was maintained at 25ºC throughout the analysis. Data analysis was conducted using the NTA software (version 8.05.14 SP7). Western blot The comprehensive procedure for Western Blotting for sEV has been previously documented in our publication (55). In brief, to assess the purity of sEV isolation, sEVs derived from mesothelioma and non-mesothelioma cancer cells were lysed by adding an equal volume of RIPA lysis and extraction buffer (Thermo Fisher, USA). The protein concentration of the sEVs was quantified using a Pierce BCA protein assay kit (Pierce Biotechnology), following the manufacturer's protocol. For western blot analysis, EV proteins (2×10 8 particles; ~5µg) were separated using Bolt™ 4-12% Bis-Tris Plus Gels (Invitrogen, USA). Samples were diluted in 4X Bolt™ LDS Sample Buffer (Thermo Fisher) and heated at 70ºC for 10 minutes before transfer onto polyvinylidene difluoride (PVDF) membranes (Thermo Fisher, USA). The PVDF membrane was blocked with 5% non-fat powdered milk in PBS-T (PBS and 0.5% Tween-20) for one hour at room temperature, followed by overnight incubation at 4ºC with primary antibodies against human CD63, CD9, and CD81 (1:500 in PBS-T) separately. Subsequently, the blots were incubated with an appropriate HRP-conjugated goat anti-mouse IgG secondary antibody (1:2000) in PBS-T for 1 hour at room temperature. After each incubation step, the blots were washed three times with PBS-T buffer for 5 minutes each, followed by visualization using SuperSignal™ West Dura Extended Duration Substrate (Thermofisher, USA). The CD63, CD9, and CD81 proteins were resolved under non-reducing conditions, where no DTT 0.1M was added to the samples, defining a non-reducing condition, to detect tetraspanin markers (CD63, CD81, and CD9). Cryo electron microscopy (Cryo-EM) Cryo-electron microscopy (cryo-EM) was utilized to examine the morphology of small extracellular vesicles (sEVs) isolated via ultracentrifugation. In this procedure, approximately 4.5 μl of sEV sample (equivalent to around 10^6 particles) was applied onto glow discharged Quantifoil R2/2 copper grids (Quantifoil Micro Tools). The grids were then blotted for 2.5 seconds in a chamber maintained at 95% humidity before being plunged into liquid ethane using a Lecia EM GP device (Leica Microsystem). Imaging was conducted using a Talos Arctica cryoTEM (Thermo Fisher Scientific) operating at 200kV, with the specimen maintained at liquid nitrogen temperatures. Images were captured at 28000× magnification using a Falcon 3EC direct detector camera operated in linear mode. RNA extraction, cDNA synthesis and digital PCR from sEV samples Isolation of total RNA from the sEVs was carried out using TRIzol LS according to the manufacturer’s instructions. The extracted RNA samples were then quantified using the NanoDrop™ One Microvolume UV-Vis Spectrophotometer (Thermo Scientific), followed by cDNA synthesis using the High-Capacity cDNA Reverse Transcription Kit (4368813, Applied Biosystems, USA). Subsequently, digital PCR was performed utilizing the QIAcuity Probe PCR Kit (250102, Qiagen, USA) following the manufacturer’s protocol, with the same PCR conditions as mentioned above. Statistical analysis Statistical analysis was performed using GraphPad Prism (ver. 8) to determine statistically significant upregulated circRNAs in the PM, normal mesothelial and non-PM cell lines as well as the sEVs using a one-way analysis of variance (ANOVA). Results yielding a p value of <0.05 was considered statistically significant. Conclusion In this study, the sEV-derived hsa_circ_0007386 was found to be an effective and novel biomarker for pleural mesothelioma, suggesting that they may be involved in the occurrence and development of PM. This mechanism remains to be further explored. This study has the potential to be used in clinical applications based on less-invasive liquid biopsy, which will be able to replace conventional tissue biopsies in the near future and provide novel potential treatment options for mesothelioma patients. The finding has significant implications for the diagnosis and treatment of PM, which currently has a poor prognosis after diagnosis. Declarations Data availability All datasets are presented in the main manuscript as well as in supporting file and there would be no additional data to be deposited in any dataset. Acknowledgement The authors acknowledge the use of the Cryo Electron Microscopy Facility through the Victor Chang Cardiac Research Institute Innovation Centre, funded by the NSW government, and the Electron Microscope Unit within the Mark Wainwright Analytical Centre (MWAC) at UNSW Sydney. This study was partially funded by the NSW Dust Diseases Authority (iCARE) 2023/24 ideas to action grant. Author contributions SZ conceptualized, optimized, and carried out the experiments, analysed and interpreted the data and wrote the manuscript. JL analyzed data and contributed to manuscript preparation. MLY contributed to data interpretation. AC contributed to manuscript preparation. MEW and YYC contributed to the conceptualisation of the study, data interpretation and manuscript writing. All authors approved the final version of the manuscript. References Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(12):2081-90. Zhang W, Wu X, Wu L, Zhang W, Zhao X. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma. Annals of translational medicine. 2015;3(13):182. Faig J, Howard S, Levine EA, Casselman G, Hesdorffer M, Ohar JA. Changing pattern in malignant mesothelioma survival. Translational oncology. 2015;8(1):35-9. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, De Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479-95. Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17(8):475-88. Escalon JG, Harrington KA, Plodkowski AJ, Zheng J, Capanu M, Zauderer MG, et al. Malignant pleural mesothelioma: are there imaging characteristics associated with different histologic subtypes on computed tomography? 2018;42(4):601. Wu L, Amjad S, Yun H, Mani S, de Perrot MJSr. A panel of emerging EMT genes identified in malignant mesothelioma. 2022;12(1):1-16. Manfredi M, Martinotti S, Gosetti F, Ranzato E, Marengo E. The secretome signature of malignant mesothelioma cell lines. J Proteomics. 2016;145:3-10. Ishtiaq A, Salmon Ahmed T, Sundas T. Malignant mesothelioma. Pak J Med Sci. 2013. Munson PB. Exosomes And Their Role In Asbestos Exposure And Mesothelioma: Graduate College Dissertations and Theses. ; 2019. Robinson BW MA, Lake RA. . Malignant mesothelioma. Lancet. 2005;366(9483):397-408. Lagniau S, Lamote K, van Meerbeeck JP, Vermaelen KYJO. Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot? Oncotarget 2017;8(32):53751. Whiteside TL. The emerging role of plasma exosomes in diagnosis, prognosis and therapies of patients with cancer. Contemp Oncol (Pozn). 2018;22(1a):38-40. Munson P, Shukla A. Potential Roles of Exosomes in the Development and Detection of Malignant Mesothelioma: An Update. Int J Mol Sci. 2022;23(23). Witwer KW, Buzás EI, Bemis LT, Bora A, Lässer C, Lötvall J, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013;2. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750. Xu R, Greening DW, Zhu HJ, Takahashi N, Simpson RJ. Extracellular vesicle isolation and characterization: toward clinical application. The Journal of clinical investigation. 2016;126(4):1152-62. Nawaz M, Camussi G, Valadi H, Nazarenko I, Ekström K, Wang X, et al. The emerging role of extracellular vesicles as biomarkers for urogenital cancers. Nature reviews Urology. 2014;11(12):688-701. Greening DW, Gopal SK, Mathias RA, Liu L, Sheng J, Zhu HJ, et al. Emerging roles of exosomes during epithelial-mesenchymal transition and cancer progression. Seminars in cell & developmental biology. 2015;40:60-71. Szempruch AJ, Sykes SE, Kieft R, Dennison L, Becker AC, Gartrell A, et al. Extracellular vesicles from Trypanosoma brucei mediate virulence factor transfer and cause host anemia. Cell. 2016;164(1-2):246-57. Gangoda L, Boukouris S, Liem M, Kalra H, Mathivanan S. Extracellular vesicles including exosomes are mediators of signal transduction: are they protective or pathogenic? Proteomics. 2015;15(2-3):260-71. Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Mark MT, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329-35. Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang W-C, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 2015;527(7576):100-4. Andreu Z, Yáñez-Mó M. Tetraspanins in extracellular vesicle formation and function. Frontiers in immunology. 2014;5:442. Van Niel G, Porto-Carreiro I, Simoes S, Raposo G. Exosomes: a common pathway for a specialized function. Journal of biochemistry. 2006;140(1):13-21. Skog J, Würdinger T, Van Rijn S, Meijer DH, Gainche L, Curry WT, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature cell biology. 2008;10(12):1470-6. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177-82. Kourembanas S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annual review of physiology. 2015;77:13-27. Nawaz M, Fatima F, Nazarenko I, Ekström K, Murtaza I, Anees M, et al. Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery. Expert review of proteomics. 2016;13(4):395-409. Rak J. Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Frontiers in pharmacology. 2013;4:21. Panda AC, Grammatikakis I, Munk R, Gorospe M, Abdelmohsen K. Emerging roles and context of circular RNAs. Wiley Interdiscip Rev RNA. 2017;8(2). Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32(5):453-61. Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17(4):205-11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25(8):981-4. Lasda E, Parker R. Circular RNAs Co-Precipitate with Extracellular Vesicles: A Possible Mechanism for circRNA Clearance. PLoS One. 2016;11(2):e0148407. ORAL ABSTRACTS. Asia-Pacific Journal of Clinical Oncology. 2018;14(S7):50-90. Kalluri R. The biology and function of exosomes in cancer. J Clin Invest. 2016;126(4):1208-15. Bai H, Lei K, Huang F, Jiang Z, Zhou X. Exo-circRNAs: a new paradigm for anticancer therapy. Mol Cancer. 2019;18(1):56. Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Research. 2015;25(8):981-4. Zhong S, Zhou S, Yang S, Yu X, Xu H, Wang J, et al. Identification of internal control genes for circular RNAs. Biotechnol Lett. 2019;41(10):1111-9. Trevethan R. Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice. Front Public Health. 2017;5:307. Li J, Li Z, Jiang P, Peng M, Zhang X, Chen K, et al. Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. J Exp Clin Cancer Res. 2018;37(1):177. Zhang X, Zhou H, Jing W, Luo P, Qiu S, Liu X, et al. The Circular RNA hsa_circ_0001445 Regulates the Proliferation and Migration of Hepatocellular Carcinoma and May Serve as a Diagnostic Biomarker. Dis Markers. 2018;2018:3073467. Lu J, Wang YH, Yoon C, Huang XY, Xu Y, Xie JW, et al. Circular RNA circ-RanGAP1 regulates VEGFA expression by targeting miR-877-3p to facilitate gastric cancer invasion and metastasis. Cancer Lett. 2020;471:38-48. Shi H, Huang S, Qin M, Xue X, Guo X, Jiang L, et al. Exosomal circ_0088300 Derived From Cancer-Associated Fibroblasts Acts as a miR-1305 Sponge and Promotes Gastric Carcinoma Cell Tumorigenesis. Front Cell Dev Biol. 2021;9:676319. Zhang Q, Wang Z, Cai H, Guo D, Xu W, Bu S, et al. CircPLK1 Acts as a Carcinogenic Driver to Promote the Development of Malignant Pleural Mesothelioma by Governing the miR-1294/HMGA1 Pathway. Biochem Genet. 2022;60(5):1527-46. Cheng YY, Yuen ML, Rath EM, Johnson B, Zhuang L, Yu TK, et al. CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence In Situ Hybridisation. Front Oncol. 2020;10:579327. Ding HX, Lv Z, Yuan Y, Xu Q. The expression of circRNAs as a promising biomarker in the diagnosis and prognosis of human cancers: a systematic review and meta-analysis. Oncotarget. 2018;9(14):11824-36. Stella M, Falzone L, Caponnetto A, Gattuso G, Barbagallo C, Battaglia R, et al. Serum Extracellular Vesicle-Derived circHIPK3 and circSMARCA5 Are Two Novel Diagnostic Biomarkers for Glioblastoma Multiforme. Pharmaceuticals (Basel). 2021;14(7). Huang XY, Huang ZL, Huang J, Xu B, Huang XY, Xu YH, et al. Exosomal circRNA-100338 promotes hepatocellular carcinoma metastasis via enhancing invasiveness and angiogenesis. J Exp Clin Cancer Res. 2020;39(1):20. He C, Zheng S, Luo Y, Wang B. Exosome Theranostics: Biology and Translational Medicine. Theranostics. 2018;8(1):237-55. Endzeliņš E, Berger A, Melne V, Bajo-Santos C, Soboļevska K, Ābols A, et al. Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. BMC Cancer. 2017;17(1):730. Zhand S, Zhu Y, Nazari H, Sadraeian M, Warkiani ME, Jin D. Thiolate DNAzymes on Gold Nanoparticles for Isothermal Amplification and Detection of Mesothelioma-derived Exosomal PD-L1 mRNA. Anal Chem. 2023;95(6):3228-37. Zhand S, Xiao K, Razavi Bazaz S, Zhu Y, Bordhan P, Jin D, et al. Improving capture efficiency of human cancer cell derived exosomes with nanostructured metal organic framework functionalized beads. Applied Materials Today. 2021;23:100994. Additional Declarations No competing interests reported. Supplementary Files Supportinginformation.pdf Cite Share Download PDF Status: Published Journal Publication published 14 Jun, 2024 Read the published version in Cells → Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4107936","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":288750234,"identity":"59a2ce66-e122-4744-9bad-299e6ce9dc6e","order_by":0,"name":"Sareh Zhand","email":"","orcid":"","institution":"School of Biomedical Engineering, University of Technology Sydney","correspondingAuthor":false,"prefix":"","firstName":"Sareh","middleName":"","lastName":"Zhand","suffix":""},{"id":288750235,"identity":"00714ca4-b994-40a2-92ad-b212f3f3c724","order_by":1,"name":"Jiayan Liao","email":"","orcid":"","institution":"Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney","correspondingAuthor":false,"prefix":"","firstName":"Jiayan","middleName":"","lastName":"Liao","suffix":""},{"id":288750236,"identity":"ecd1142c-28b8-4989-a514-b939464b4a11","order_by":2,"name":"Alessandro Castorina","email":"","orcid":"","institution":"Laboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Sciences, Faculty of Science, University of Technology Sydney.","correspondingAuthor":false,"prefix":"","firstName":"Alessandro","middleName":"","lastName":"Castorina","suffix":""},{"id":288750237,"identity":"e57f5926-8cff-4c05-9a8d-c5f5f404cffc","order_by":3,"name":"Man Lee Yuen","email":"","orcid":"","institution":"Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney","correspondingAuthor":false,"prefix":"","firstName":"Man","middleName":"Lee","lastName":"Yuen","suffix":""},{"id":288750238,"identity":"23cfd63c-e75d-423b-af6c-9f041cb0b527","order_by":4,"name":"Majid Ebrahimi Warkiani","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABDElEQVRIiWNgGAWjYHCChAM8IIqHsYGBwcAGIsZDgpY0iGoCWhiQVR0mrEW3/cDDA28YDsub9xxu/FxQcD5xP/8Bxgdv2xjkDQ5g12J2JiHh4ByGw4ZzzjY2S88wuJ3YI5HAbDi3jcFwAy4tBxISDvMw3Gacwc/YIM0D1sLAJs3bxsCIU8v5B2At9kAtzb95DM4l9vAfYP8N1GKPU8sNiC2JM3gb24C2HEjsYUhgYwZqScSt5QHQLwb/k2fwHGyz5jFINu65kdgsOeecRPJMnA7LSf7wpiLNdgZP+uPbPH/sZNv7Dx/88KbMxrYPhxZgFCQAYxBFBBSnDBK41AMBO07DRsEoGAWjYBRAAACp6WAYLIszjgAAAABJRU5ErkJggg==","orcid":"","institution":"Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney","correspondingAuthor":true,"prefix":"","firstName":"Majid","middleName":"Ebrahimi","lastName":"Warkiani","suffix":""},{"id":288750239,"identity":"14589c0c-c432-4686-a401-57ef8ff51f48","order_by":5,"name":"Yuen Yee Cheng","email":"","orcid":"","institution":"Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney","correspondingAuthor":false,"prefix":"","firstName":"Yuen","middleName":"Yee","lastName":"Cheng","suffix":""}],"badges":[],"createdAt":"2024-03-15 12:46:15","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4107936/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4107936/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.3390/cells13121037","type":"published","date":"2024-06-14T15:11:22+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":54439596,"identity":"ec2c94ae-1cee-4d01-a6f4-6f8d17fe7cec","added_by":"auto","created_at":"2024-04-10 14:46:16","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":949747,"visible":true,"origin":"","legend":"\u003cp\u003eSchematic diagram showing an overview of the circRNA detection procedure using cultured cells as the starting material. In step 1, the PM, non-PM and normal mesothelium cell lines were cultured in specific culture medium. In step 2.1 sEVs were isolated from cell culture conditioned medium using ultracentrifuge and characterized. In step 2.2 the Cell containing the desired CircRNA (hsa_circ_0007386) were harvested and the cell pellet isolated. In step 3 total RNA was extracted from the isolated sEVs and the cell pellets, cDNA was reverse transcribed from the total RNA using random hexamer and finally the copy number of hsa_circ_0007386 circRNA in the samples was measured using the digital PCR assay using specific designed primer/probe sets.\u003c/p\u003e","description":"","filename":"Figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-4107936/v1/c27be677c301492256a335b2.png"},{"id":54439595,"identity":"d87c0b0c-24f4-4e7e-af96-0f1d50becc2f","added_by":"auto","created_at":"2024-04-10 14:46:16","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":3033579,"visible":true,"origin":"","legend":"\u003cp\u003esEV characterization. A) For Western Blot analysis, sEVs were loaded on SDS-PAGE and immunoblotted for antibodies against tetraspanins [anti-CD9, anti-CD63, and anti-CD81]. A gel was run under non-reducing and reducing conditions with 2×10\u003csup\u003e8\u003c/sup\u003e particles; ~5µg. The exposure time was 35 seconds. B) The concentration of isolated sEVs based on NTA analysis (All samples were diluted 1:100). C)The size distribution of isolated sEVs showed sharp peaks between 100-200 nm. D) Cryo-EM images of isolated sEVs from cell culture supernatant are shown (Scale bar: 100 nm). The extracted sEVs displayed perfect integrity with an average size of 100 nm.\u003c/p\u003e","description":"","filename":"Figure2Updated.png","url":"https://assets-eu.researchsquare.com/files/rs-4107936/v1/df1c51e134f91ad88785dc1c.png"},{"id":54439590,"identity":"51303578-d04a-46d4-a802-eabc7c034848","added_by":"auto","created_at":"2024-04-10 14:46:15","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":330066,"visible":true,"origin":"","legend":"\u003cp\u003eRNA-binding sites matching for hsa_circ_0007386.\u003c/p\u003e","description":"","filename":"Figure3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4107936/v1/45f1e6f610dc97674ef2bda5.jpg"},{"id":54439589,"identity":"d3aa4c4e-fa52-4126-946d-3f821d99b94f","added_by":"auto","created_at":"2024-04-10 14:46:15","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":2382290,"visible":true,"origin":"","legend":"\u003cp\u003eThe copy number of specific hsa_circ_0007386 in A) PM cell lines, and non-PM cell lines, compared to B) PM cell derived sEVs, and non-PM cell derived sEV using the digital PCR. Copy numbers of the circRNA were normalised using the internal reference control \u003ca href=\"http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284\" target=\"_blank\"\u003ehsa_circ_0000284\u003c/a\u003e.\u003c/p\u003e","description":"","filename":"Figure4.png","url":"https://assets-eu.researchsquare.com/files/rs-4107936/v1/348b6441a05a6e0115aed00c.png"},{"id":54439592,"identity":"dd1e47eb-37d7-4349-9945-42a519c7e667","added_by":"auto","created_at":"2024-04-10 14:46:15","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":1362820,"visible":true,"origin":"","legend":"\u003cp\u003eThe copy number ratio of specific hsa_circ_0007386 to the reference circular RNA has_circ_0000284 in the A) PM cell derived sEV, and B) PM cell lines compared to the normal mesothelial cell derived sEVs (MeT5A) and normal microglial cell (BV-2) derived sEV and cell lines using the digital PCR. The copy number of circRNA was normalised using the internal reference control \u003ca href=\"http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284\" target=\"_blank\"\u003ehsa_circ_0000284\u003c/a\u003e. In data analysis the significancy showed by stars and the P value\u0026lt;0.0001 showed by ****, The P value 0.0017 showed by ** and P value 0.015 showed by *.\u003c/p\u003e","description":"","filename":"Figure5.png","url":"https://assets-eu.researchsquare.com/files/rs-4107936/v1/55ccd4d5ba9cc9c2368bd5a3.png"},{"id":54439575,"identity":"f00d51bd-ef06-42a5-94b1-b7f0e166f939","added_by":"auto","created_at":"2024-04-10 14:46:14","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":1342943,"visible":true,"origin":"","legend":"\u003cp\u003eThe copy number of specific hsa_circ_0007386 in the A) PM cell derived sEV, compared to the non-PM cell derived sEVs (HepG2, and H1975) and B) PM cell lines compared to the non-PM cell lines (H1975) using the digital PCR. The copy number of has_circ_0007386 in both PM cells and sEV derived was significantly higher compared to the non-PM cell lines which showed higher ratio of has_circ_0007386 to the reference has_circ_0000284. In data analysis the significancy showed by stars and the P value\u0026lt;0.0001 showed by ****, and P value 0.011 showed by *.\u003c/p\u003e","description":"","filename":"Figure6.png","url":"https://assets-eu.researchsquare.com/files/rs-4107936/v1/af769ad7a5fafcade2ef16a9.png"},{"id":58822831,"identity":"a804601a-17f6-4337-9445-99c142156aa9","added_by":"auto","created_at":"2024-06-21 16:48:12","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":12799244,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4107936/v1/dded9378-8ff0-4fc2-af2e-1d17e42b6532.pdf"},{"id":54439591,"identity":"24736f21-b9e0-461e-887b-d364b7105baf","added_by":"auto","created_at":"2024-04-10 14:46:15","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":337907,"visible":true,"origin":"","legend":"","description":"","filename":"Supportinginformation.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4107936/v1/d5411a3e9369dc0bbcc49460.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Small extracellular vesicle-derived circular RNA hsa_circ_0007386 as a biomarker for the diagnosis of Pleural Mesothelioma","fulltext":[{"header":"Introduction","content":"\u003cp\u003ePleural mesothelioma (PM) is an aggressive cancer of the lung lining that occurs as a result of previous asbestos exposure either occupationally or environmentally (1). The lack of specific biomarkers and different pathologic subtypes increase the difficulty of diagnosis and treatment. PM patients are usually diagnosed at an advanced stage and are usually short lived with median survival ranging from 4 to 18 months (2, 3) and five year survival rate currently stands at less than 5% (4). Additionally, therapeutic options for PM patients who are not eligible for surgery are very limited (5). There are three main histological subtypes of PM: epithelioid, biphasic, and sarcomatoid (6). While epithelioid PM shows a morphology similar to normal pleura, biphasic and sarcomatoid subtypes are associated with a worse prognosis than the epithelioid subtype (7). The PM exhibits a highly secretory cell type, releasing factors that can exert autocrine or paracrine effects on nearby tumor and stromal cells. These released factors likely contribute to the modulation of the extracellular environment and could potentially serve as a source for identifying cancer biomarkers(8). Current procedures for PM diagnosis are invasive and can take a long time to reach a definitive result (9-11). As the incidence of PM continues to rise, there is a pressing need for novel biomarkers for early detection. These tools and biomarkers are crucial for effective clinical management of PM, facilitating early diagnosis, monitoring prognosis, and predicting treatment outcomes (12).\u003c/p\u003e\n\u003cp\u003eIn recent times, extracellular vesicles (EVs) have garnered attention as significant messengers facilitating communication between tumor cells and their surrounding microenvironment. These extracellular vesicles have emerged as key mediators in cancer biology, orchestrating cellular communication crucial to tumorigenesis and harbouring distinctive cancer biomarker profiles (13). EVs stand as promising candidates for both diagnosis and therapy owing to their detectability in non-invasive blood samples and other body fluids. This characteristic suggests significant potential for their application in diagnostic and therapeutic endeavours. The EVs released from mesothelioma cells provide crucial insights into the molecules and signalling pathways pivotal in the initiation and advancement of the tumour (14). As delineated by the International Society of Extracellular Vesicles (ISEV), the designation \u0026quot;small extracellular vesicles\u0026quot; is the recommended nomenclature for the diverse array of vesicles derived from cell culture supernatants or physiological fluids. (15, 16). EVs, particularly small extracellular vesicles (sEVs), represent a heterogeneous population of lipid-bilayer-delimited particles released from cells that are classified based on size (17-19). This nano sized particles (30\u0026ndash;150 nm) originating from the endosomal pathway, play essential roles in both physiological and pathological phenomena, (22, 23), encompassing crucial functions in immune response (20), signal transduction (21), as well as tumor initiation, progression, invasion, and metastasis (22, 23). These vesicles exhibit enrichment in a repertoire of shared structural and functional proteins, including tetraspanins (CD9, CD81, CD82, and CD63) (24), Rab GTPase, and HSP90 (heat shock protein 90), among others (25). Furthermore, sEVs transport a diverse cargo comprising of proteins, nucleic acids (mRNA, regulatory RNA, and DNA components), lipids, metabolites, and organelles from donor cells. Recent findings suggest that these reservoirs of biomarkers hold promise for advancing early cancer detection, prognostication, and monitoring tumor progression. (26-28). In recent investigations, it has been established that Osteopontin, Galectin-1, Mesothelin, and VEGF exhibit elevated concentrations in sEVs derived from PM patients\u0026apos; effusions in comparison to those from the benign group (14). Furthermore, another study revealed increased expression levels of Galectin-1, Mesothelin, Osteopontin, and VEGF in PM patients relative to benign patients (15) (15). Some EV biomarkers were found to be abundant in the serum of mice exposed to asbestos, as well as elevated levels of exosomal ceruloplasmin, haptoglobin, and fibulin-1 (16). The sEVs represent a largely untapped resource of diagnostic, prognostic, and predictive biomarkers with significant potential for clinical applications. (18, 29, 30).\u003c/p\u003e\n\u003cp\u003eCircular RNA (circRNA) presents a distinct form of non-coding RNA characterized by its closed single-stranded structure lacking 5\u0026rsquo; caps or 3\u0026rsquo; poly(A) tails, setting it apart from linear messenger RNA (mRNA)(31). They are originating from pre-mRNAs through a process termed back splicing (32). CircRNAs exhibit remarkable stability in the bloodstream and possess a longer half-life compared to linear RNAs. Additionally, they exhibit resistance to exonuclease-mediated degradation, rendering them highly attractive candidates for blood-based diagnostic applications (33). Recent investigations have unveiled a correlation between circRNA overexpression and tumorigenesis across various cancers, encompassing lung malignancies (including PM), liver, breast, prostate, bladder, colorectal, ovarian, central nervous system, stomach, as well as diverse haematological malignancies (34). Published findings indicate a significant enrichment of circRNAs within sEVs, with levels exceedingly at least two-fold those observed in parental cells (35). Recent studies highlighted the abundance and stability of circular RNAs within sEVs, suggesting their persistent functionality after up taking by neighbouring cells (35). Exo-circRNAs produced by tumors are released into bodily fluids, where they exert effects on various aspects including diagnosis, suppression of metastasis, and induction of tumor cell apoptosis (44). It has been suggested that cells may transfer circRNAs by excreting them in sEVs, acting as messengers in cell-to-cell communication, and studies also propose that the clearance of intracellular circRNAs may be associated with sEVs (36). There is currently limited knowledge on circRNA expression in PM (37) and CircRNA expression in sEV derived from PM has not been explored yet. This study aims to use the digital PCR (dPCR) for an accurate detection of the most frequently upregulated circRNA in PM (hsa_circ_0007386) in sEVs derived from PM, non-PM and normal mesothelial cell lines and compare the expression of this specific circRNA with non-PM and normal mesothelial cell line to determine its suitability as potential biomarker candidate for the early diagnosis of PM (Fig. 1).\u003c/p\u003e"},{"header":"Result and Discussion","content":"\u003cp\u003eThe sEVs exist in various body fluids, which is convenient for non-invasive detection (38). CircRNAs are stable, conservative, and specific expression of cells and tissues, which suggests that they have the potential to be used as molecular diagnostic and prognostic markers (39). sEV derived circRNAs combine the advantages of using sEVs with the specificity of circRNAs, enhancing their potential application as early non-invasive biomarkers. sEVs derived from pathological cells can carry their disease-specific circRNA into the peripheral blood. Therefore, the detection of sEV-derived circRNAs in serum may be feasible in the diagnosis of tumor disease. CircRNAs have also been considered as EV biomarkers to monitor the progression and chemoresistance of some type of cancers. In addition, it has been discovered that circRNAs are stably expressed in sEVs and these circRNAs are suggested to be a promising candidate for biomarkers in cancer (40).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCircRNA expression profile in mesothelioma\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAccording to results of our previous study (37), 290 circRNAs derived from host genes PHKB, SLC45A4, ARHGEF28, FBXW4, TAF15, PLEKHM1, RALGPS1, STIL, L3MBTL4, ANKRD27, NHS, ILKAP, and PTK2 in PM cell lines were upregulated using high throughput human lncRNA microarrays through fold change (FC) (37). For this paper, we selected hsa_circ_0007386 (the one most highly expressed in four mesothelioma cells) as a representative circRNA for the PHKB gene (37) and investigated for changes in its expression levels to determine whether it could be employed as a potential biomarker for PM diagnosis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003esEV characterization\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFor sEV characterization, particle size and concentration were evaluated by NTA, the morphology was evaluated with Cryo-EM and the expression of the sEV common protein markers (CD63, CD81, and CD9) was assessed using Western blotting (Fig.2). The tetraspanins (CD63, CD81, and CD9) were detected in the sEVs derived from studied cell line using Western Blotting (Fig. 2 A \u0026amp; Fig. 1A-E Supplementary information). The size distribution of sEVs, measured by NTA and the concentration of sEVs enriched from cells is shown in Fig. 2B. As shown in Fig. 2C, most of the particles had a mean size of 100-200 nm. For more and precise characterisation of the sEVs, the Cryo-EM imaging was performed. Under cryo-EM, the specimens were imaged under extremely low temperature (below \u0026minus; 175 \u0026deg;C) so that sEVs retained its original spherical shape. The results of cryo-EM for sEVs confirmed their expected size and morphology (Fig. 2D).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe hsa_circ_0007386 RNA binding sites.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNumerous databases are available for RNA binding sites to circRNA targets. In this study, we have used the Circular RNA interactome database (https://circinteractome.nia.nih.gov/) to find out the RNA-binding sites matching. The results are listed in Fig. 3.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe hsa_circ_0007386 highly expressed in PM cell lines and sEVs. \u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFor the digital PCR analysis, the negative control for the hsa_circ_0007386 was used to adjust the threshold for achieving the correct signal from the positive samples and the signal detected from the top right corner of the quadruplet, regarded as a positive control. In all samples, the background signal was used as the threshold above which signals were considered positive. Results of digital PCR revealed that among the studied cell lines, the hsa_circ_0007386 was overexpressed in NCI H-28 cells, with 1218.3 copies per \u0026micro;L input sample, followed by the H2052, H226, H2452, and MSTO-211H, with 696.7, 555.6, 412.5, and 187 copies per \u0026micro;L, respectively. The normal mesothelial cell line (MeT5A) showed 448 copies per \u0026micro;L. By normalizing the copy numbers using the ratio of hsa_circ_0007386 to hsa_circ_0000284, ratios were 0.183, 0.168, 0.098, 0.0943, and 0.0908 respectively (Fig. 4A). Based on findings by Zhong at al.,(41) hsa_circ_0000284 was selected as the internal control due to its demonstrated superior stability. This characteristic renders it an optimal candidate not only for circRNAs but also for broader RNA applications, serving as a reliable reference gene (41). The results also indicate that the copy number ratio of hsa_circ_0007386 to the circ RNA reference was significantly lower in non-PM cell lines including melanoma (Colo794; 0.0340, Colo679;0.0042, A375; 0.00755), gastric (Kato III; 0.0467, MKN45;0.0066), lung (H460; 0.031, H3122; 0.0167), colon (HCT 115;0.0216, HCT 116;0.0323), breast (MCF-7; 0.0235), liver (HepG2;0.068), and prostate (LnCAP; 0.00433) cancer cell lines (p\u0026lt;0.0001). \u003c/p\u003e\n\u003cp\u003ethe hsa_circ_0007386 was overexpressed in H226 derived sEVs, with 36.23 copy per \u0026micro;L, followed by MSTO-211H, H2452, H2052, and NCI-H28, with 23, 11.71, 9.54, and 6.77 copies per \u0026micro;L of mixture, respectively. By normalizing the copy numbers found in sEVs using the hsa_circ_0007386 to hsa_circ_0000284 ratio, results differed from those attained using cells RNA extracts, and so did the ranking across cell lines as follows; H2452, NCI-H28, MSTO-211H, H2052, and H226 with the following ratios 0.187, 0.171, 0.121, 0.1045, and 0.087, respectively (Fig. 4B). Interestingly, the copy number ratio of this circRNA biomarker to the circ RNA reference was significantly lower in non-PM cell lines including melanoma (Colo 794; 0.0580, Colo679;0.0053, A375; 0.0084), gastric (Kato III; 0.055, MKN45;0.0054), lung (H460; 0.036, H3122; 0.032,), colon (HCT 116;0.0452, HCT 115; 0.018), breast (MCF-7; 0.0233), and prostate (LnCAP; 0.0066) cancer cell lines (p\u0026lt;0.0001). Indicating that the sorting of specific circRNA species to sEVs compared to the cells may be actively regulated.\u003c/p\u003e\n\u003cp\u003eResults of our study revealed the specificity of the has_circ_0007386 derived from both cells and sEVs as a specific biomarker for early diagnosis of PM, as we have observed significant expression of this biomarker in the PM cell derived sEVs (Fig. 5A) and PM cell lines (Fig. 5B) compared to the normal mesothelial cell line (Met5A) and the microglial cell line (BV-2) (p\u0026lt;0.0001).\u003c/p\u003e\n\u003cp\u003eThe results of our study on PM and non-PM cells derived RNAs confirm the 90% sensitivity and 93.3% specificity of the hsa_circ_0007386 as a biomarker in PM diagnosis. However, this number was 81.81% and 87.5% in the sEV respectively. The specificity was calculated by dividing the number of true negative samples which are here non-PM cell lines to the sum of true negative and false positive which are here sum pf non-PM cell lines and the cell lines that shows higher ratio of has_circ_0007386 to reference circRNA compared to the PM cell lines (42). Similarly for the sensitivity calculation, the number of true positive samples which are here PM cell lines to the sum of true positive and false negative which are here sum of PM cell lines and the cell lines that shows higher ratio of has_circ_0007386 to reference circRNA compared to the PM cell lines (42). While our results demonstrate consistencies in the copy numbers or copy number ratios of hsa_circ_0007386 and hsa_circ_0000284 between PM, and non-PM derived sEV samples and their corresponding cellular counterparts, the findings also reveal a higher copy number ratio of hsa_circ_0007386 to the reference hsa_circ_0000284 in sEV-derived samples compared to the cells. The heightened presence of hsa_circ_0007386 within PM-derived sEVs, as compared to its cellular counterpart, underscores the propensity of circRNAs for encapsulation within sEVs. By scrutinizing the contents of sEVs, we can attain more precise and sensitive findings than those derived from the analyses of cellular extracts alone. Notably, our investigation revealed the maximal copy number of sEV-derived hsa_circ_0007386 within MSTO-211H, representative of the biphasic variant of PM. Early identification of this PM subtype holds substantial promise for advancing our understanding of disease progression. Consequently, the potential clinical value of sEV-derived hsa_circ_0007386 in less-invasive liquid biopsy approaches deserves consideration, with the outlook of replacing traditional tissue biopsies in the future. Our findings underscore the diagnostic specificity of hsa_circ_0007386 as a viable biomarker for early PM detection, with significantly elevated expression observed in PM cell lines compared to non-PM, normal mesothelial, and other cancer cell lines (p-value \u0026lt; 0.0001). This highlights the promising diagnostic potential of hsa_circ_0007386 across both sEV and cellular contexts. To ensure precision and reliability, further validation utilizing patient samples is imperative for consolidating these outcomes. In different stages of different development diseases, disease-related circRNA can be sorted into sEVs to be enriched and transported to target cells or target organs for release. Many studies have shown that differential expression of sEV-derived circRNAs in the body fluid was associated with the pathological characteristics of tumor vascular invasion, lymph node metastasis, poor survival and TNM stage (43-45). Studies have shown that circRNAs can be packaged and function in sEVs (46). However, the mechanism behind the selective packaging of specific circRNAs into sEVs is not yet clear and requires further investigation. In a study by Zhang et al (47), it was showed that circRNA polo-like kinase 1 (circPLK1) was upregulated in Malignant Pleural Mesothelioma (MPM) tumor tissues and cell lines. CircPLK1 knockdown suppressed the proliferation, migration, invasion and stemness of MPM cells in MPM progression. The studies mentioned have indicated the diagnostic efficacy of different circ-RNAs as a cancer marker. \u003c/p\u003e\n\u003cp\u003eIn the PM cell derived sEVs, a notable observation arose when comparing the copy number ratio of hsa_circ_0007386 to the circRNA reference across various PM cell derived sEVs, particularly in the context of one lung cancer cell line (H1975), and one liver cancer (HepG2). Despite an apparently higher ratio in H1975 (0.1630), and HepG2 (0.086) compared to other PM cell lines (H20525, MSTO-211H, and H226) a deeper analysis utilizing raw data and absolute copy number calculations revealed that the observed copy number of this putative circRNA biomarker in the above-mentioned cell lines did exhibit statistical significance (p\u0026lt;0.0001) (Fig. 6A). The decision to employ exact copy number calculations was driven by the criterion of fewer than 100 copies per 40 \u0026micro;L of digital PCR sample, aiming to enhance result accuracy. Similarly, in the PM cell lines, comparable to our observations in the cell derived sEVs, a notable observation arose when comparing the copy number ratio of hsa_circ_0007386 to the circRNA reference across various PM cell lines, particularly in the context of one lung cancer cell line (H1975). Despite an apparently higher ratio in H1975 (0.12) compared to other PM cell lines (MSTO-211H, H226, and H2452), a deeper analysis utilizing raw data and absolute copy number calculations revealed that the observed copy number of this putative circRNA biomarker in the H1975 cell line did exhibit statistical significance (p\u0026lt;0.0001) (Fig. 6B). The decision to employ exact copy number calculations was driven by the criterion of fewer than 100 copies per 40 \u0026micro;L of digital PCR sample, aiming to enhance result accuracy (48).\u003c/p\u003e\n\u003cp\u003eResults of a systematic review and meta-analysis revealed that circRNAs have the potential to be biomarkers for diagnosis and prognosis of cancers (49). It has been described by Stella et al. that two circRNAs that localised in serum derived sEVs including circSMARCA5 (hsa_circ_0001445) and circHIPK3 (hsa_circ_0000284) could be potential biomarkers for glioblastoma and could distinguish glioblastoma patients from healthy controls with high accuracy (50). In contrast, another study has reported that the continued high expression of sEV derived circRNA-100338 in the serum of HCC HCC (Hepatocellular Carcinoma) patients undergoing therapeutic hepatectomy may be related to lung metastasis and poor survival (51). \u003c/p\u003e\n\u003cp\u003eThere are some advantages in analyzing sEV-encapsulated non-coding RNAs compared to whole plasma/serum. Firstly, as extracellular vesicles can be secreted by a variety of cells, the contents of sEVs can be used as biomarkers for diagnosis or prognosis in various diseases (52). Secondly, it is easier to sort circRNA into sEVs than linear RNAs (35). In addition, sEVs derived from cancers contain highly specific RNA, and they can also prevent the nucleic acid molecules from degradation by RNase in the blood (53). However, there are still many issues to be resolved before sEVs-derived circRNAs can be employed as reliable biomarkers, such as preservation of specimens, cell source of sEVs, sEVs isolation methods, etc.\u003c/p\u003e\n\u003cp\u003eFuture investigations focusing on sEV circRNAs in various biological contexts, such as the hematopoietic system, immune response, nervous disorders, cancer development, and other diseases, will provide further insights into the enigmatic nature of sEV circRNAs. Consequently, elucidating the mechanisms of cancer pathogenesis and identifying potential novel diagnostic biomarkers or therapeutic targets are expected to be prominent areas of research in the future.\u003c/p\u003e"},{"header":"Materials and methods","content":"\u003cp\u003e\u003cstrong\u003eReagents\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe list of following antibodies including purified anti-human CD63 (Clone H5C6), purified anti-human CD9 (Clone HI9a), and purified anti-human CD81 (Clone 5A6) antibodies, along with the secondary antibody HRP-goat anti-mouse IgG (405306), were purchased from BioLegend (USA). BenchMark\u0026trade; Pre-stained Protein Ladder (10748010) and Novex\u0026trade; Sharp Pre-stained Protein Standard (LC5800) were obtained from ThermoFisher (USA). RIPA Lysis and Extraction Buffer (89900), Pierce BCA protein assay kit (23227), 4X Bolt\u0026trade; LDS Sample Buffer (B0007), polyvinylidene difluoride (PVDF) transfer membranes (88585), Bolt\u0026trade; 4-12% Bis-Tris Plus Gels (NW04120BOX), Glycogen (R0561), and SuperSignal\u0026trade; West Dura Extended Duration Substrate (37071) were purchased from Life Technologies (Australia). TRIzol LS (10296010, Invitrogen, USA), phosphate buffered saline (PBS), Bovine serum albumins (A3059-10G), Chloroform (288306-1L), Isopropanol (I9516-500ML), Ethyl alcohol (E7023), and 1,4-dithiothreitol (DTT) (10197777001) were purchased from Sigma Aldrich (USA). High-Capacity cDNA Reverse Transcription Kit (4368813) was purchased from Applied Biosystems, USA. The QIAcuity Probe PCR Kit (250102), and QIAcuity Nanoplate 26k 24-well (250001) was purchased from Qiagen, USA.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCell culture\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e1 and repeatedly tested negative for mycoplasma in house at UTS. All cells were maintained in RPMI 1640 (Gibco, UK) supplemented with 10% (v/v) fetal calf serum (FCS, Gibco, UK), 100 U/mL penicillin and 100 mg/mL streptomycin (Gibco, UK) in a T25 tissue culture flask (ThermoFisher, USA) The cultures were maintained at 37\u0026deg;C in a humidified incubator with 5% CO\u003csub\u003e2\u003c/sub\u003e and for BV-2 cell line the RPMI 1460 was replaced with DMEM: F12.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTotal RNA Isolation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe comprehensive procedure for RNA isolation has been previously documented in our publication (54). In brief, approximately 1\u0026times;10\u003csup\u003e6\u003c/sup\u003e cell pellets were utilized for the isolation of total RNA using the TRIzol extraction method. Following the manufacturer\u0026rsquo;s protocol, 750\u0026micro;L of TRIzol Reagent was combined with 250\u0026micro;L of cell pellets, and the mixture was homogenized through repeated pipetting. After a 5-minute incubation to ensure complete dissociation of the nucleoprotein complex, 200\u0026micro;L of chloroform was added for lysis and incubated at room temperature for 2\u0026ndash;3 minutes. Subsequently, the samples underwent centrifugation at 12,000 \u0026times; g for 15 minutes at 4\u0026deg;C, resulting in phase separation. The upper aqueous phase, containing the RNA, was transferred to a new tube, and 500\u0026micro;L of isopropanol along with 1 \u0026micro;L of Glycogen was added, followed by a 10-minute incubation. After centrifugation at 12,000 \u0026times; g for 10 minutes at 4\u0026deg;C, the RNA precipitate formed a white gel-like pellet at the bottom of the tube, and the supernatant was discarded. The pellet was then resuspended in 1 mL of 75% ethanol and centrifuged at 7500 \u0026times; g for 5 minutes at 4\u0026deg;C. Following removal of the supernatant, the RNA pellet was air dried for 5\u0026ndash;10 minutes, then resuspended in 20 \u0026micro;L of RNase-free water and incubated in a heat block at 60\u0026deg;C for 15 minutes. Finally, the RNA samples were stored at \u0026ndash;70\u0026deg;C for subsequent use. Quantification of the extracted RNA samples was performed using the NanoDrop\u0026trade; One Microvolume UV-Vis Spectrophotometer (Thermo Scientific).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ecDNA Synthesis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e1\u0026micro;g of total RNA was subjected to first-strand complementary DNA (cDNA) synthesis using a high-capacity cDNA reverse transcription kit (4368813, Applied Biosystems, USA) consisting of random hexamers and additional 50\u0026micro;M of Oligo dT primer, in the following conditions: primer annealing at 25\u0026deg;C for 10 minutes, cDNA synthesis at 37\u0026deg;C for 2 hours, denaturing at 85\u0026deg;C for 5 minutes and for 1 cycle using a CFX96 PCR system (Bio-Rad, Hercules, CA, USA). The cDNA was stored at -20\u0026ordm;C for further experiments.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCircRNA detection via digital PCR\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe digital PCR was done using the QIAcuity Probe PCR kit (250102, Qiagen, USA) according to manufacturer\u0026rsquo;s protocol. 1x concentration of probe PCR master mix, 0.8 \u0026mu;M forward primer (hsa_circ_0007386), 0.8 \u0026mu;M reverse primer (hsa_circ_0007386), and 0.4 \u0026mu;M probe (hsa_circ_0007386), 12\u0026micro;L of each synthesized cDNA sample in a total volume of 40\u0026mu;L was added to the Nanoplate 26k (Qiagen, USA). Similarly, Amplification conditions consisted of 1 cycle of 95˚C for 2 min following 40 cycles of 95˚C for 15 sec, and 60˚C for 30 seconds with plate read. The cycling and detection were performed on QIAcuity digital PCR system. All experiments were normalized with respective hsa_circ_0000284 as a reference gene expression. Hsa_circ_0000284 is utilized as a reference gene for this study in order to normalize the detected circRNA copy number variation for each tested sample. The prime/ probes used in the study are listed in our previous work (37).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePreparation of conditioned medium (CM)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe comprehensive procedure for preparing CM has been previously documented in our earlier publication (55). Briefly, for CM preparation from the above-mentioned cell lines, the cells were initially cultured in T175 tissue culture flasks (ThermoFisher, USA). Upon reaching approximately 70% confluency, equivalent to approximately 3\u0026times;10\u003csup\u003e8\u003c/sup\u003e cells, the supernatant was carefully removed, and the cells underwent two washes with phosphate-buffered saline (PBS). Subsequently, the cells were transferred to sEV-free medium (RPMI 1640/DMEM: F12 without FCS) and cultured for 48 hours at 37\u0026deg;C in a humidified incubator set at 5% CO\u003csub\u003e2\u003c/sub\u003e and 2% O\u003csub\u003e2\u003c/sub\u003e (hypoxic conditions). Following incubation, the culture medium was collected for further experimentation.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSmall EV isolation from CM using ultracentrifugation.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe comprehensive procedure for sEV isolation has been previously documented in our publication (54). The media containing released EVs was initially subjected to centrifugation steps to eliminate cellular debris. This process involved centrifugation at 300 \u0026times;g (19776 rotor, Sigma, USA) for 10 minutes to remove dead cells and debris, followed by a subsequent centrifugation at 2,000 \u0026times;g (19776 rotor, Sigma, USA) for 20 minutes to further eliminate debris. The resulting cell-free supernatant was then transferred to a new tube and centrifuged at 10,000 \u0026times;g (19776 rotor, Sigma, USA) for 30 minutes to pellet microvesicles. The supernatant containing EVs was subsequently filtered through a sterile 0.22 \u0026micro;m syringe filter (Merck Millipore, USA) and subjected to ultracentrifugation at 100,000 \u0026times;g for 120 minutes (F37L Ti rotor, Beckman Coulter, USA) to pellet small EVs (sEVs). After removal of the supernatant, pellets containing EVs and contaminating proteins were re-suspended in a separate ultracentrifuge tube in phosphate-buffered saline (PBS) and centrifuged again at 100,000 \u0026times;g for 120 minutes. The supernatant was discarded, and the pellet was resuspended in 500 \u0026micro;L of PBS, previously filtered through a 0.22 \u0026micro;m syringe filter (WHA9913-2502, Sigma Aldrich, USA). The isolated sEVs were stored at -80\u0026deg;C until further use. All centrifugation steps were conducted at 4\u0026ordm;C.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eNanoparticle tracking analysis.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFor nanoparticle tracking analysis (NTA), a ZetaView\u0026reg; PMX-420 QUATT system (Particle Metrix, Germany) equipped with a 532nm green laser was employed to determine the concentration and size distribution of small extracellular vesicles (sEVs). Isolated sEV samples (100\u0026micro;L) were diluted to 500\u0026micro;L using freshly filtered PBS (0.22\u0026micro;m filter) and injected into the detection chamber via syringe. The camera settings, including a slider shutter at 650 and slider gain at 50, were manually adjusted and maintained consistently across all samples. Videos lasting 30 seconds were recorded, with 5 captures per sample. The detection threshold was set at 6, while blur and max jump distance were automatically configured. The temperature was maintained at 25\u0026ordm;C throughout the analysis. Data analysis was conducted using the NTA software (version 8.05.14 SP7).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eWestern blot\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe comprehensive procedure for Western Blotting for sEV has been previously documented in our publication (55). In brief, to assess the purity of sEV isolation, sEVs derived from mesothelioma and non-mesothelioma cancer cells were lysed by adding an equal volume of RIPA lysis and extraction buffer (Thermo Fisher, USA). The protein concentration of the sEVs was quantified using a Pierce BCA protein assay kit (Pierce Biotechnology), following the manufacturer\u0026apos;s protocol. For western blot analysis, EV proteins (2\u0026times;10\u003csup\u003e8\u003c/sup\u003e particles; ~5\u0026micro;g) were separated using Bolt\u0026trade; 4-12% Bis-Tris Plus Gels (Invitrogen, USA). Samples were diluted in 4X Bolt\u0026trade; LDS Sample Buffer (Thermo Fisher) and heated at 70\u0026ordm;C for 10 minutes before transfer onto polyvinylidene difluoride (PVDF) membranes (Thermo Fisher, USA). The PVDF membrane was blocked with 5% non-fat powdered milk in PBS-T (PBS and 0.5% Tween-20) for one hour at room temperature, followed by overnight incubation at 4\u0026ordm;C with primary antibodies against human CD63, CD9, and CD81 (1:500 in PBS-T) separately. Subsequently, the blots were incubated with an appropriate HRP-conjugated goat anti-mouse IgG secondary antibody (1:2000) in PBS-T for 1 hour at room temperature. After each incubation step, the blots were washed three times with PBS-T buffer for 5 minutes each, followed by visualization using SuperSignal\u0026trade; West Dura Extended Duration Substrate (Thermofisher, USA). The CD63, CD9, and CD81 proteins were resolved under non-reducing conditions, where no DTT 0.1M was added to the samples, defining a non-reducing condition, to detect tetraspanin markers (CD63, CD81, and CD9).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCryo electron microscopy (Cryo-EM)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCryo-electron microscopy (cryo-EM) was utilized to examine the morphology of small extracellular vesicles (sEVs) isolated via ultracentrifugation. In this procedure, approximately 4.5 \u0026mu;l of sEV sample (equivalent to around 10^6 particles) was applied onto glow discharged Quantifoil R2/2 copper grids (Quantifoil Micro Tools). The grids were then blotted for 2.5 seconds in a chamber maintained at 95% humidity before being plunged into liquid ethane using a Lecia EM GP device (Leica Microsystem). Imaging was conducted using a Talos Arctica cryoTEM (Thermo Fisher Scientific) operating at 200kV, with the specimen maintained at liquid nitrogen temperatures. Images were captured at 28000\u0026times; magnification using a Falcon 3EC direct detector camera operated in linear mode.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRNA extraction, cDNA synthesis and digital PCR from sEV samples\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIsolation of total RNA from the sEVs was carried out using TRIzol LS according to the manufacturer\u0026rsquo;s instructions. The extracted RNA samples were then quantified using the NanoDrop\u0026trade; One Microvolume UV-Vis Spectrophotometer (Thermo Scientific), followed by cDNA synthesis using the High-Capacity cDNA Reverse Transcription Kit (4368813, Applied Biosystems, USA). Subsequently, digital PCR was performed utilizing the QIAcuity Probe PCR Kit (250102, Qiagen, USA) following the manufacturer\u0026rsquo;s protocol, with the same PCR conditions as mentioned above.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eStatistical analysis was performed using GraphPad Prism (ver. 8) to determine statistically significant upregulated circRNAs in the PM, normal mesothelial and non-PM cell lines as well as the sEVs using a one-way analysis of variance (ANOVA). Results yielding a p value of \u0026lt;0.05 was considered statistically significant.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eIn this study, the sEV-derived hsa_circ_0007386 was found to be an effective and novel biomarker for pleural mesothelioma, suggesting that they may be involved in the occurrence and development of PM. This mechanism remains to be further explored. This study has the potential to be used in clinical applications based on less-invasive liquid biopsy, which will be able to replace conventional tissue biopsies in the near future and provide novel potential treatment options for mesothelioma patients. The finding has significant implications for the diagnosis and treatment of PM, which currently has a poor prognosis after diagnosis.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eData availability\u003c/h2\u003e\n\u003cp\u003eAll datasets are presented in the main manuscript as well as in supporting file and there would be no additional data to be deposited in any dataset.\u003c/p\u003e\n\u003ch2\u003eAcknowledgement\u003c/h2\u003e\n\u003cp\u003eThe authors acknowledge the use of the Cryo Electron Microscopy Facility through the Victor Chang Cardiac Research Institute Innovation Centre, funded by the NSW government, and the Electron Microscope Unit within the Mark Wainwright Analytical Centre (MWAC) at UNSW Sydney. This study was partially funded by the NSW Dust Diseases Authority (iCARE) 2023/24 ideas to action grant.\u003c/p\u003e\n\u003ch2\u003eAuthor contributions\u003c/h2\u003e\n\u003cp\u003eSZ conceptualized, optimized, and carried out the experiments, analysed and interpreted the data and wrote the manuscript. JL analyzed data and contributed to manuscript preparation. MLY contributed to data interpretation. AC contributed to manuscript preparation. MEW and YYC contributed to the conceptualisation of the study, data interpretation and manuscript writing. All authors approved the final version of the manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eTsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(12):2081-90.\u003c/li\u003e\n\u003cli\u003eZhang W, Wu X, Wu L, Zhang W, Zhao X. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma. Annals of translational medicine. 2015;3(13):182.\u003c/li\u003e\n\u003cli\u003eFaig J, Howard S, Levine EA, Casselman G, Hesdorffer M, Ohar JA. Changing pattern in malignant mesothelioma survival. Translational oncology. 2015;8(1):35-9.\u003c/li\u003e\n\u003cli\u003eScherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, De Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479-95.\u003c/li\u003e\n\u003cli\u003eYap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17(8):475-88.\u003c/li\u003e\n\u003cli\u003eEscalon JG, Harrington KA, Plodkowski AJ, Zheng J, Capanu M, Zauderer MG, et al. Malignant pleural mesothelioma: are there imaging characteristics associated with different histologic subtypes on computed tomography? 2018;42(4):601.\u003c/li\u003e\n\u003cli\u003eWu L, Amjad S, Yun H, Mani S, de Perrot MJSr. A panel of emerging EMT genes identified in malignant mesothelioma. 2022;12(1):1-16.\u003c/li\u003e\n\u003cli\u003eManfredi M, Martinotti S, Gosetti F, Ranzato E, Marengo E. The secretome signature of malignant mesothelioma cell lines. J Proteomics. 2016;145:3-10.\u003c/li\u003e\n\u003cli\u003eIshtiaq A, Salmon Ahmed T, Sundas T. Malignant mesothelioma. Pak J Med Sci. 2013.\u003c/li\u003e\n\u003cli\u003eMunson PB. Exosomes And Their Role In Asbestos Exposure And Mesothelioma: Graduate College Dissertations and Theses. ; 2019.\u003c/li\u003e\n\u003cli\u003eRobinson BW MA, Lake RA. . Malignant mesothelioma. Lancet. 2005;366(9483):397-408.\u003c/li\u003e\n\u003cli\u003eLagniau S, Lamote K, van Meerbeeck JP, Vermaelen KYJO. Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot? Oncotarget 2017;8(32):53751.\u003c/li\u003e\n\u003cli\u003eWhiteside TL. The emerging role of plasma exosomes in diagnosis, prognosis and therapies of patients with cancer. Contemp Oncol (Pozn). 2018;22(1a):38-40.\u003c/li\u003e\n\u003cli\u003eMunson P, Shukla A. Potential Roles of Exosomes in the Development and Detection of Malignant Mesothelioma: An Update. Int J Mol Sci. 2022;23(23).\u003c/li\u003e\n\u003cli\u003eWitwer KW, Buz\u0026aacute;s EI, Bemis LT, Bora A, L\u0026auml;sser C, L\u0026ouml;tvall J, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013;2.\u003c/li\u003e\n\u003cli\u003eTh\u0026eacute;ry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750.\u003c/li\u003e\n\u003cli\u003eXu R, Greening DW, Zhu HJ, Takahashi N, Simpson RJ. Extracellular vesicle isolation and characterization: toward clinical application. The Journal of clinical investigation. 2016;126(4):1152-62.\u003c/li\u003e\n\u003cli\u003eNawaz M, Camussi G, Valadi H, Nazarenko I, Ekstr\u0026ouml;m K, Wang X, et al. The emerging role of extracellular vesicles as biomarkers for urogenital cancers. Nature reviews Urology. 2014;11(12):688-701.\u003c/li\u003e\n\u003cli\u003eGreening DW, Gopal SK, Mathias RA, Liu L, Sheng J, Zhu HJ, et al. Emerging roles of exosomes during epithelial-mesenchymal transition and cancer progression. Seminars in cell \u0026amp; developmental biology. 2015;40:60-71.\u003c/li\u003e\n\u003cli\u003eSzempruch AJ, Sykes SE, Kieft R, Dennison L, Becker AC, Gartrell A, et al. Extracellular vesicles from Trypanosoma brucei mediate virulence factor transfer and cause host anemia. Cell. 2016;164(1-2):246-57.\u003c/li\u003e\n\u003cli\u003eGangoda L, Boukouris S, Liem M, Kalra H, Mathivanan S. Extracellular vesicles including exosomes are mediators of signal transduction: are they protective or pathogenic? Proteomics. 2015;15(2-3):260-71.\u003c/li\u003e\n\u003cli\u003eHoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Mark MT, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329-35.\u003c/li\u003e\n\u003cli\u003eZhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang W-C, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 2015;527(7576):100-4.\u003c/li\u003e\n\u003cli\u003eAndreu Z, Y\u0026aacute;\u0026ntilde;ez-M\u0026oacute; M. Tetraspanins in extracellular vesicle formation and function. Frontiers in immunology. 2014;5:442.\u003c/li\u003e\n\u003cli\u003eVan Niel G, Porto-Carreiro I, Simoes S, Raposo G. Exosomes: a common pathway for a specialized function. Journal of biochemistry. 2006;140(1):13-21.\u003c/li\u003e\n\u003cli\u003eSkog J, W\u0026uuml;rdinger T, Van Rijn S, Meijer DH, Gainche L, Curry WT, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature cell biology. 2008;10(12):1470-6.\u003c/li\u003e\n\u003cli\u003eMelo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177-82.\u003c/li\u003e\n\u003cli\u003eKourembanas S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annual review of physiology. 2015;77:13-27.\u003c/li\u003e\n\u003cli\u003eNawaz M, Fatima F, Nazarenko I, Ekstr\u0026ouml;m K, Murtaza I, Anees M, et al. Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery. Expert review of proteomics. 2016;13(4):395-409.\u003c/li\u003e\n\u003cli\u003eRak J. Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Frontiers in pharmacology. 2013;4:21.\u003c/li\u003e\n\u003cli\u003ePanda AC, Grammatikakis I, Munk R, Gorospe M, Abdelmohsen K. Emerging roles and context of circular RNAs. Wiley Interdiscip Rev RNA. 2017;8(2).\u003c/li\u003e\n\u003cli\u003eJeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32(5):453-61.\u003c/li\u003e\n\u003cli\u003eChen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17(4):205-11.\u003c/li\u003e\n\u003cli\u003eHanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.\u003c/li\u003e\n\u003cli\u003eLi Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25(8):981-4.\u003c/li\u003e\n\u003cli\u003eLasda E, Parker R. Circular RNAs Co-Precipitate with Extracellular Vesicles: A Possible Mechanism for circRNA Clearance. PLoS One. 2016;11(2):e0148407.\u003c/li\u003e\n\u003cli\u003eORAL ABSTRACTS. Asia-Pacific Journal of Clinical Oncology. 2018;14(S7):50-90.\u003c/li\u003e\n\u003cli\u003eKalluri R. The biology and function of exosomes in cancer. J Clin Invest. 2016;126(4):1208-15.\u003c/li\u003e\n\u003cli\u003eBai H, Lei K, Huang F, Jiang Z, Zhou X. Exo-circRNAs: a new paradigm for anticancer therapy. Mol Cancer. 2019;18(1):56.\u003c/li\u003e\n\u003cli\u003eLi Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Research. 2015;25(8):981-4.\u003c/li\u003e\n\u003cli\u003eZhong S, Zhou S, Yang S, Yu X, Xu H, Wang J, et al. Identification of internal control genes for circular RNAs. Biotechnol Lett. 2019;41(10):1111-9.\u003c/li\u003e\n\u003cli\u003eTrevethan R. Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice. Front Public Health. 2017;5:307.\u003c/li\u003e\n\u003cli\u003eLi J, Li Z, Jiang P, Peng M, Zhang X, Chen K, et al. Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. J Exp Clin Cancer Res. 2018;37(1):177.\u003c/li\u003e\n\u003cli\u003eZhang X, Zhou H, Jing W, Luo P, Qiu S, Liu X, et al. The Circular RNA hsa_circ_0001445 Regulates the Proliferation and Migration of Hepatocellular Carcinoma and May Serve as a Diagnostic Biomarker. Dis Markers. 2018;2018:3073467.\u003c/li\u003e\n\u003cli\u003eLu J, Wang YH, Yoon C, Huang XY, Xu Y, Xie JW, et al. Circular RNA circ-RanGAP1 regulates VEGFA expression by targeting miR-877-3p to facilitate gastric cancer invasion and metastasis. Cancer Lett. 2020;471:38-48.\u003c/li\u003e\n\u003cli\u003eShi H, Huang S, Qin M, Xue X, Guo X, Jiang L, et al. Exosomal circ_0088300 Derived From Cancer-Associated Fibroblasts Acts as a miR-1305 Sponge and Promotes Gastric Carcinoma Cell Tumorigenesis. Front Cell Dev Biol. 2021;9:676319.\u003c/li\u003e\n\u003cli\u003eZhang Q, Wang Z, Cai H, Guo D, Xu W, Bu S, et al. CircPLK1 Acts as a Carcinogenic Driver to Promote the Development of Malignant Pleural Mesothelioma by Governing the miR-1294/HMGA1 Pathway. Biochem Genet. 2022;60(5):1527-46.\u003c/li\u003e\n\u003cli\u003eCheng YY, Yuen ML, Rath EM, Johnson B, Zhuang L, Yu TK, et al. CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence In Situ Hybridisation. Front Oncol. 2020;10:579327.\u003c/li\u003e\n\u003cli\u003eDing HX, Lv Z, Yuan Y, Xu Q. The expression of circRNAs as a promising biomarker in the diagnosis and prognosis of human cancers: a systematic review and meta-analysis. Oncotarget. 2018;9(14):11824-36.\u003c/li\u003e\n\u003cli\u003eStella M, Falzone L, Caponnetto A, Gattuso G, Barbagallo C, Battaglia R, et al. Serum Extracellular Vesicle-Derived circHIPK3 and circSMARCA5 Are Two Novel Diagnostic Biomarkers for Glioblastoma Multiforme. Pharmaceuticals (Basel). 2021;14(7).\u003c/li\u003e\n\u003cli\u003eHuang XY, Huang ZL, Huang J, Xu B, Huang XY, Xu YH, et al. Exosomal circRNA-100338 promotes hepatocellular carcinoma metastasis via enhancing invasiveness and angiogenesis. J Exp Clin Cancer Res. 2020;39(1):20.\u003c/li\u003e\n\u003cli\u003eHe C, Zheng S, Luo Y, Wang B. Exosome Theranostics: Biology and Translational Medicine. Theranostics. 2018;8(1):237-55.\u003c/li\u003e\n\u003cli\u003eEndzeliņ\u0026scaron; E, Berger A, Melne V, Bajo-Santos C, Soboļevska K, Ābols A, et al. Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. BMC Cancer. 2017;17(1):730.\u003c/li\u003e\n\u003cli\u003eZhand S, Zhu Y, Nazari H, Sadraeian M, Warkiani ME, Jin D. Thiolate DNAzymes on Gold Nanoparticles for Isothermal Amplification and Detection of Mesothelioma-derived Exosomal PD-L1 mRNA. Anal Chem. 2023;95(6):3228-37.\u003c/li\u003e\n\u003cli\u003eZhand S, Xiao K, Razavi Bazaz S, Zhu Y, Bordhan P, Jin D, et al. Improving capture efficiency of human cancer cell derived exosomes with nanostructured metal organic framework functionalized beads. Applied Materials Today. 2021;23:100994.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Pleural Mesothelioma, small extracellular vesicle, circular RNA, digital PCR","lastPublishedDoi":"10.21203/rs.3.rs-4107936/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4107936/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"Pleural mesothelioma (PM) is a highly aggressive tumor that is caused by asbestos exposure and lacks effective therapeutic regimens. Current procedures for PM diagnosis are invasive and can take a long time to reach a definitive result. Small extracellular vesicles (sEVs) have been identified as important communicators between tumour cells and their microenvironment via their cargo including circular RNAs (circRNAs). CircRNAs are thermodynamically stable, highly conserved and it has been found to be dysregulated in cancer. This study aimed to identify potential biomarker for PM diagnosis by investigating the expression of specific circRNA gene pattern (hsa_circ_0007386) in cells and sEVs using digital polymerase chain reaction (dPCR). For this reason, 5 PM, 14 non-PM, and one normal mesothelial cell line were cultured. The sEV were isolated from the cells using the gold standard ultracentrifuge method. The RNA was extracted from both cells and sEVs, cDNA was synthesised, and dPCR was run. Results showed that hsa_circ_0007386 was significantly overexpressed in PM cell lines and sEVs compared to non-PM and normal mesothelial cell lines (p\u003c0.0001). The upregulation of hsa_circ_0007386 in PM highlights its potential as a diagnostic biomarker. This study underscores the importance and potential of circRNAs and sEVs as cancer diagnostic tools.","manuscriptTitle":"Small extracellular vesicle-derived circular RNA hsa_circ_0007386 as a biomarker for the diagnosis of Pleural Mesothelioma","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-04-10 14:46:07","doi":"10.21203/rs.3.rs-4107936/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"fabf8860-e0a0-4c85-bf6c-aef6aef076a3","owner":[],"postedDate":"April 10th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":30398221,"name":"Biological sciences/Cancer"},{"id":30398222,"name":"Biological sciences/Molecular biology"},{"id":30398223,"name":"Health sciences/Biomarkers"}],"tags":[],"updatedAt":"2024-06-21T15:11:22+00:00","versionOfRecord":{"articleIdentity":"rs-4107936","link":"https://doi.org/10.3390/cells13121037","journal":{"identity":"cells","isVorOnly":true,"title":"Cells"},"publishedOn":"2024-06-14 15:11:22","publishedOnDateReadable":"June 14th, 2024"},"versionCreatedAt":"2024-04-10 14:46:07","video":"","vorDoi":"10.3390/cells13121037","vorDoiUrl":"https://doi.org/10.3390/cells13121037","workflowStages":[]},"version":"v1","identity":"rs-4107936","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4107936","identity":"rs-4107936","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}